Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBIT (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of EBIT data on record, last reported at -$33.0 million in Q3 2025.

  • For Q3 2025, EBIT fell 24.31% year-over-year to -$33.0 million; the TTM value through Sep 2025 reached $8.5 million, up 106.6%, while the annual FY2024 figure was -$81.1 million, 43.4% up from the prior year.
  • EBIT reached -$33.0 million in Q3 2025 per GLUE's latest filing, down from -$15.6 million in the prior quarter.
  • Across five years, EBIT topped out at $44.0 million in Q1 2025 and bottomed at -$37.2 million in Q2 2023.
  • Average EBIT over 3 years is -$20.8 million, with a median of -$33.0 million recorded in 2025.
  • The widest YoY moves for EBIT: up 226.01% in 2025, down 24.31% in 2025.
  • A 3-year view of EBIT shows it stood at -$34.9 million in 2023, then surged by 137.3% to $13.0 million in 2024, then plummeted by 353.58% to -$33.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$33.0 million in Q3 2025, -$15.6 million in Q2 2025, and $44.0 million in Q1 2025.